Search

Ion Beam Applications

Fechado

10.54 -1.5

Visão Geral

Variação de preço das ações

24h

Atual

Mín

10.2

Máximo

10.8

Indicadores-chave

By Trading Economics

Rendimento

-10M

Vendas

206M

P/E

Médio do Setor

41.111

63.778

Rendimento de Dividendos

1.56

Margem de lucro

-4.99

Funcionários

1,943

EBITDA

-372K

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

1.56%

2.39%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

342M

Abertura anterior

12.04

Fecho anterior

10.54

Ion Beam Applications Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de set. de 2024, 06:28 UTC

Aquisições, Fusões, Aquisições de Empresas

EQT Leads $102.5 Million Series A Funding Round in Belgian Radioisotope Producer PanTera

Ion Beam Applications Previsão

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ion Beam Applications

Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures. The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH. It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.